NOVO-NORDISK A/S-SPONS ADR (NVO) Stock News
NYSE:NVO - New York Stock Exchange, Inc. - US6701002056 - ADR - Currency: USD
NVO Latest News, Press Relases and Analysis
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) – A Strong Growth Stock with Reasonable Valuation
NOVO-NORDISK (NYSE:NVO) offers strong growth, high profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth stocks.
Magnificent 7 Crush EU Giants—Jamie Dimon Tells Europe: 'You're Losing'
Jamie Dimon warns Europe is falling behind the U.S. economically. Market caps show an even wider gap as U.S. tech giants dominate.
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady.
Mentions: LLY
Novo Nordisk Receives Boost on $2.34B Italian Factory
Novo Nordisk A/S (NYSE:NVO) is one of the 10 best defensive stocks to buy in a volatile market. On July 7, the company received a significant boost in its proposed $2.34 billion investment in a factory in Rome, Italy. Italian authorities have already appointed Francesco Rocca as president of the Lazio region, which includes Rome. […]
Mentions: VZ
Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
2 Stocks to Buy on the Dip and Hold for 10 Years
DexCom has significant room to grow in its core market, despite disappointing results last year. One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. Two great examples today in the healthcare sector are Novo Nordisk (NYSE: NVO) and DexCom (NASDAQ: DXCM).
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
Is Hims & Hers Stock in Trouble?
Hims & Hers Health and Novo Nordisk announced a partnership a few months ago, and it has already come to an end. Novo Nordisk is concerned about the telehealth company's practices, particularly relating to compounded drugs. Hims & Hers Health (NYSE: HIMS) is a telehealth company that offers personalized solutions for its customers.
Mentions: HIMS
How Novo Nordisk misread the US market for its weight loss sensation
COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, leaving the Danish drugmaker in a more vulnerable position when rival Eli Lilly entered the market, six former employees involved in the discussions told Reuters. Novo has enjoyed a tremendous windfall of $46 billion (292 billion Danish crowns) in net profit since mid-2021, when Wegovy became the first highly effective obesity treatment approved in the United States. In response, Novo is reorganizing its leadership team following the surprise ouster of Chief Executive Lars Fruergaard Jorgensen.
Mentions: LLY
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Hardman Johnston Global Equity Sold Novo Nordisk (NVO) due to Weak Script Trends
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The strategy returned 0.43%, net of fees, in the quarter compared to -1.32% for the MSCI AC World Net Index. The Portfolio experienced a solid quarter […]
Mentions: LLY
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value
